Background: IMP3, PPARG and PD-L1 have been implicated in tumorigenesis and progression in many cancers, but their significance in urothelial carcinoma remains unclear. Aim: The aim of this study is to assess the possible significance of IMP3, PPARG and PD-L1 in urothelial bladder carcinoma and determine the relation between their expressions and different clinicopathological (tumor size, grade, histological variant, muscle invasion, lymphovascular invasion and pathologic T stage) and molecular variables. Methods: This study aimed to evaluate immunohistochemical expression of IMP3, PPARG and PD-L1 and correlate them with clinicopathological and molecular variables. Results: IMP3 was significantly correlated to muscle invasion (P<0.01), tumor grade (P<0.05), histological variant (P<0.05), lymphovascular invasion (P<0.01) and PT stage (P<0.01). PPARG was inversely correlated to muscle invasion (P<0.01), tumor grade (P<0.01), histological variant (P<0.01), PT stage (P<0.05) and molecular subtype (P<0.01).  PD-L1 was significantly correlated to muscle invasion (P<0.05), histological variant (P<0.05) and PT stage (P<0.01). IMP3 and PD-L1 showed high statistically significant correlation (P<0.01). IMP3 and PPARG showed inverse statistically significant correlation (P<0.05). No significant correlation between PPARG and PD-L1expression was detected (P>0.05).Conclusions: IMP3 may be used as a prognostic marker. PPARG may be used to identify the luminal molecular subtype. PD-L1 may be used as a prognostic marker for tumor aggressiveness, so it may be used in immunotherapy.